$Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study$

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study

Abstract Objectives This study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF). Methods A prospective observational study was conducted from May 2022 to May 2023, focusi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yinge Zhan, Liu Li, Jie Zhou, Yishan Ma, Xuchong Guan, Suo Wang, Ya Chang
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Series:	BMC Cardiovascular Disorders
Subjects:	Vericiguat Heart failure with reduced ejection fraction Cardiopulmonary exercise testing
Online Access:	https://doi.org/10.1186/s12872-025-04477-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
by: Robert J.H. Miller, et al.
Published: (2022-06-01)

Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
by: Eiichi Akiyama, et al.
Published: (2020-06-01)

Clinical characteristics and outcomes in Asian patients with heart failure with mildly reduced ejection fraction
by: Julian Cheong Kiat Tay, et al.
Published: (2024-07-01)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)

Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial
by: Djawid Hashemi, et al.
Published: (2020-06-01)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
by: Enrique Santas, et al.
Published: (2020-06-01)

Electrocardiography-based artificial intelligence predicts the upcoming future of heart failure with mildly reduced ejection fraction
by: Dae-Young Kim, et al.
Published: (2025-02-01)

Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
by: Anouk Achten, et al.
Published: (2025-04-01)

Impact of Initial Heart Rate, Diastolic Pressure, and Pulse Pressure on Prognostic Outcomes in Heart Failure Patients with Mildly Reduced Ejection Fraction
by: Hu H, et al.
Published: (2025-01-01)

Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity
by: Bas M. van Dalen, et al.
Published: (2025-02-01)

Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction
by: Tomoyuki Hamada, et al.
Published: (2022-06-01)

Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care
by: Daniela Tomasoni, et al.
Published: (2022-06-01)

Chronic obstructive pulmonary disease and heart failure in real life: the tip of the iceberg in the sea of comorbidities. A prospective observational study
by: Ombretta Para, et al.
Published: (2025-02-01)

Clinical study on the treatment of chronic heart failure with a novel D‐shant atrium shunt device
by: Xiaoke Shang, et al.
Published: (2022-06-01)

Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post‐discharge
by: Patrick Rossignol, et al.
Published: (2020-06-01)

Sacubitril/valsartan on right ventricular-pulmonary artery coupling and albumin-bilirubin score in heart failure in Chinese patients with reduced ejection fraction
by: Yanan Shi, et al.
Published: (2025-01-01)

Association between prognosis and the use of angiotensin‐converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction
by: Akihiro Sunaga, et al.
Published: (2022-06-01)

Short‐term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan
by: Simone Mazzetti, et al.
Published: (2020-06-01)

Safety and efficacy of catheter ablation in atrial fibrillation patients with heart failure with preserved ejection fraction
by: Songbing Long, et al.
Published: (2025-01-01)

AdipoRon ameliorates the progression of heart failure with preserved ejection fraction via mitigating lipid accumulation and fibrosis
by: Wuping Tan, et al.
Published: (2025-02-01)

The Usefulness of Soluble ST2 Concentration in Heart Failure with Reduced Ejection Fraction to Predict Severe Impairment in Exercise Capacity Assessed in Cardiopulmonary Exercise Testing
by: Magdalena Dudek, et al.
Published: (2024-12-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Effect of atrial high-rate episodes (AHREs) on functional status and quality of life (QoL) in heart failure—cardiac resynchronization therapy population
by: Lamyaa Elsayed Allam, et al.
Published: (2025-02-01)

Characteristics and Outcomes of Heart Failure Outpatients with Improvement in Ejection Fraction in Qatar
by: Rasha Kaddoura, et al.
Published: (2024-07-01)

Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature
by: Navkaranbir S. Bajaj, et al.
Published: (2020-06-01)

Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Association between insulin resistance indices and outcomes in patients with heart failure with preserved ejection fraction
by: Weicheng Ni, et al.
Published: (2025-01-01)

Exploring the association between tissue sodium content, heart failure subtypes, and symptom burden: insights from magnetic resonance imaging
by: Djawid Hashemi, et al.
Published: (2025-01-01)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
by: Rolf Wachter, et al.
Published: (2020-06-01)

Changes of the quality of life and efficiency criteria of coronary artery bypass grafting in patients with stable coronary artery disease and preserved left ventricular ejection fraction
by: Yu.A. Borkhalenko, et al.
Published: (2018-06-01)

Cardiopulmonary Exercise Testing: Deciphering Cardiovascular Complications in Systemic Sclerosis
by: Ailia Giubertoni, et al.
Published: (2025-01-01)

Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
by: Ify R. Mordi, et al.
Published: (2020-06-01)

Clinical characteristics and quality of life of patients with coronary heart disease before revascularization
by: Yu.A. Borkhalenko, et al.
Published: (2016-11-01)

Gender differences in the prognostic impact of uric acid in patients with heart failure and preserved ejection fraction
by: Xuefeng Wu, et al.
Published: (2025-01-01)

Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction
by: Shunsuke Tamaki, et al.
Published: (2020-06-01)

Characteristics of cardiopulmonary exercise capacity in adults with different degrees of obesity
by: Shukun Deng, et al.
Published: (2025-01-01)

Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF
by: Lijun Song, et al.
Published: (2025-01-01)

Variation in clinical and patient‐reported outcomes among complex heart failure with preserved ejection fraction phenotypes
by: Kelsey M. Flint, et al.
Published: (2020-06-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
by: Jenni Huusko, et al.
Published: (2020-06-01)